1 =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A-1 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 1998 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 1-12574 TEXAS BIOTECHNOLOGY CORPORATION (Exact name of Registrant as specified in its charter) Delaware 13-3532643 (State of Incorporation) (I.R.S. Employer Identification Number) 7000 Fannin, Suite 1920 Houston, Texas 77030 (713) 796-8822 (Address and telephone number of principal executive offices and zip code) ================================================================================ 2 ITEM 14(b). REPORTS ON FORM 8-K. One report on Form 8-K was filed on December 16, 1998 regarding the amendment of the NDA for NOVASTAN(R). 3 SIGNATURES PURSUANT TO THE REQUIREMENTS OF SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED, THEREUNTO DULY AUTHORIZED, IN THE CITY OF HOUSTON AND STATE OF TEXAS ON THE 31ST DAY OF MARCH, 1999. TEXAS BIOTECHNOLOGY CORPORATION By: /s/ STEPHEN L. MUELLER ---------------------------------- Stephen L. Mueller Vice President, Finance and Administration Secretary and Treasurer